Abbott Laboratories, et al., Preterm Infant Nutrition

This docket consolidates claims brought by families of premature infants who allege that cow's-milk-based fortifiers and formulas manufactured by Abbott Laboratories and other defendants caused or contributed to necrotizing enterocolitis (NEC), a serious and sometimes fatal intestinal condition in preterm infants. Centralized in April 2022 before Judge Rebecca R. Pallmeyer in the Northern District of Illinois, the docket has grown to 847 pending actions out of 1,057 total filed — a large and substantially intact population, consistent with a docket that is actively developing bellwether cases rather than one that has resolved a meaningful share of its filings.

For a funder, this is a mass tort in an active growth and development phase: general causation between cow's-milk-based products and NEC in premature infants is a contested, medically complex question, and the litigation has not yet produced a bellwether verdict or a global settlement structure in this proceeding to anchor pricing. Claims in this docket carry catastrophic-injury damages potential, given that NEC can cause death, permanent bowel injury, or long-term developmental complications, which supports meaningful advance sizing once individual medical records establishing NICU admission, feeding history, and NEC diagnosis are verified.

Medical-lien and NICU-cost exposure is substantial and central to underwriting any claim in this docket, since neonatal intensive care and any related surgical treatment generate significant billed charges that insurers and Medicaid programs will assert against recovery. Given the docket's size and active development, portfolio-level inventory finance under Criterica Capital's mass tort finance line is a reasonable structure for a firm building a book of NEC-related claims, though duration assumptions should account for the absence of a bellwether track record this early in the litigation's life. A structural brief on this docket's development is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.